OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 8 of 19

9 Barriers to Medication Adherence Several categories of factors may limit adherence to obesity pharmacotherapy. Informational Factors   ➤ Incomplete understanding of the dosing regimen.   ➤ Limited knowledge of the mechanism of action or expected outcomes.   ➤ Misconception that obesity treatment should be short-term. Psychological Factors   ➤ Barriers to engaging in new behavior (eg, consistently taking and obtaining medication).   ➤ Fear of desired medication effect changing lifestyle (eg, eating at social events, using food as a coping mechanism). Adverse Effects and Expectations   ➤ Physical discomfort from adverse effects.   ➤ Adverse effects impacting activities of daily living.   ➤ Concern regarding the onset or magnitude of weight loss leads patients to perceive the medication as ineffective. Cost and Accessibility   ➤ Inability to afford medication.   ➤ Lack of insurance coverage for medication or follow-up visits.   ➤ Lack of availability of medication.

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026